NHS hospitals are rolling out an AI blood test to screen women for womb cancer before they undergo invasive diagnostic procedures. The test targets the roughly 90,000 postmenopausal women referred annually by GPs after reporting heavy bleeding, a symptom that can indicate endometrial cancer.
Only about 10,000 of those women actually have womb cancer, meaning the majority face unnecessary invasive checks. The AI blood test acts as a gatekeeper, identifying which patients genuinely need further investigation and sparing many from procedural discomfort and clinical burden.
The technology works by analyzing blood biomarkers associated with endometrial cancer. Rather than proceeding directly to procedures like endometrial biopsies or hysteroscopies, women first take the blood test. Those with low-risk scores avoid invasive follow-up, while high-risk patients move forward for confirmation.
This approach addresses a real clinical bottleneck. The NHS endoscopy and pathology services already strain under demand. Reducing unnecessary referrals conserves resources for patients who genuinely need advanced diagnostics. It also reduces patient anxiety. Women awaiting cancer checks face psychological burden while in limbo.
The test reflects broader trends in AI-assisted diagnostics. Blood-based screening removes procedural risks like infection or uterine perforation while remaining faster and cheaper than invasive alternatives. Similar AI blood tests are now in development across oncology for breast, colorectal, and ovarian cancers.
Accuracy matters here. If the test misses true cancer cases, it creates safety risks. The fact that NHS hospitals are adopting it suggests the algorithm meets clinical validation thresholds, though specific sensitivity and specificity figures remain unclear from available reporting.
Implementation across multiple NHS sites indicates confidence in the model's reliability. Rollout timing suggests 2024 or 2025 deployment. Success will depend on